Clinical and biochemical heterogeneity of Parkinson’s disease

Close metadata

OBJECTIVE

To study correlations between oxidative stress (OS) and clinical changes in patients with neurodegenerative Parkinson’s and to identify clinical/biochemical subtypes of the disease.

MATERIAL AND METHODS

One hundred and nine people were studied, including 91 patients with neurodegenerative Parkinson’s (72 patients with Parkinson’s disease (PD); 10 with multiple system atrophy (MSA); 9 with corticobasal degeneration (CBD), average age 61.1±7.2 years), and 18 clinically healthy people (average age 55.1±9.2). OS indexes were detected for scoring of redox state in peripheral blood of patients with PD and healthy people (control group). Detection of biochemical indexes was performed in erythrocytes and mononuclear fraction and blood. The activity of glutathione reductase (GR), myeloperoxidase (MPO) and content of reduced glutathione (GSH) was estimated.

RESULTS AND CONCLUSIONS

OS is a universal mechanism and is observed in many neurodegenerative diseases. However it is possible to identify quite typical changes of redox state with group selection and their correlations with definite subtypes and PD progress, it gives opportunity, in particular, to make the differential diagnosis with atypical Parkinsonism.

Keywords:

Parkinson’s disease

oxidative stress

heterogeneity

Authors:

Khadzieva Kh.I.

Rostov State Medical University

Chernikova I.V.

Rostov State Medical University

Milyutina N.P.

Southern Federal University

Plotnikov A.A.

Southern Federal University

Received:

12.02.2020

Accepted:

10.04.2020

List of references:

Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197-211. https://doi.org/10.1016/s0197-4580(02)00065-9
Levin OS, Fedorova NV. Parkinson’s disease. Moscow: MEDpress-inform; 2015. (In Russ.).
Kim WS, Kagedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 2014;6(5):73. https://doi.org/10.1186/s13195-014-0073-2
Foguem C, Manckoundia P. Lewy Body Disease: Clinical and Pathological «Overlap Syndrome» Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr Neurol Neurosci Rep. 2018;18(5): 24-33. https://doi.org/10.1007/s11910-018-0835-5
Subramaniam RS, Chesselet M-F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol. 2013;17-32. https://doi.org/10.1016/j.pneurobio.2013.106-107:04.004
Kovalenko VR, Khabarova EA, Rzaev DA, Medvedev SP. Cellular models, genomic technologies and clinical practice: a synthesis of knowledge for the study of the mechanisms, diagnostics and treatment of Parkinson’s disease. Genes and Cells. 2017;12(2):11-28. (In Russ.). https://doi.org/10.23868/201707012
Hwang O. Role of Oxidative Stress in Parkinson’s Disease. Exp Neurobiol. 2013;22:(1):11-17. (In Russ.).
Fedorova TN, Logvinenko AA, Poleshuk VV, Illarioshkin SN. The State of Systemic Oxidative Stress during Parkinson’s Disease. Neurochemistry. 2017;34(4):344-349. (In Russ.). https://doi.org/10.7868/S1027813317040033
Graciun EC, Dronca E, Leach NV. Antioxidant enzymes activity in subjects with Parkinson’s disease under L-DOPA therapy. Human & Veterinary Medicine. 2016;8:(2):124-127. (In Russ.).
Naduthota RM, Bharath RD, Jhunjhunwala K, et al. Imaging biomarker correlates with oxidative stress in Parkinson’s disease. Neurol India. 2017;65(2):263-268.
Tapias V. Mitochondrial Dysfunction and Neurodegeneration. Front Neurosci. 2019;13:1372. https://doi.org/10.3389/fnins.2019.01372
Kaur R, Mehan S, Singh Sh. Understanding multifactorial architecture of Parkinson’s disease: pathophysiology to management. Neurol Sci. 2019;40:13-23.
Kaidery NA, Thomas B. Current Perspective of Mitochondrial Biology in Parkinson’s Disease. Neurochemistry International. 2018;117(7):91-113. https://doi.org/10.1016/j.neuint.2018.03.001
Kurt AJ. Neuropathology of Multiple System Atrophy: New Thoughts About Pathogenesis. Movement Disorders. 2014;29:14. https://doi.org/10.1002/mds.26052
Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442. https://doi.org/10.1212/wnl.17.5.427
Unified Parkinson’s Disease Rating Scale (UPDRS) [Internet]. Parkinson’s UK; Feb 5, 2020. Accessed Des 4, 2020. https://www.parkinsons.org.uk/professionals/resources/unified-parkinsons-disease-rating-scale-updrs
Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. https://doi.org/10.1016/0022-3956(75)90026-6
Sunderland T, Hill J, Mellow AM, et al. J Am Geriatr Soc. 1989;37(8):725-729. https://doi.org/10.1111/j.1532-5415.1989.tb02233.x
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55(11):1621-1626. https://doi.org/10.1212/wnl.55.11.1621
https://www.parkinsonizm.ru/?page=26 https://www.parkinsonizm.ru/?page=26
Zakharov VV, Voznesenskaya TG. Nervno-psikhicheskie narusheniya. Diagnosticheskie testy. Moscow: MEDpress-inform; 2013. p. 257-260. (In Russ.).
Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiatry. 1960;23(1):56-62. https://doi.org/10.1136/jnnp.23.1.56
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545. https://doi.org/10.1093/sleep/14.6.540
Chaudhuri K, Pal S, Di Marco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629-635. https://doi.org/10.1136/jnnp.73.6.629
Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012;27(7):913-916. https://doi.org/10.1002/mds.25037
Guo JD, Zhao X, Li Y, Liu XL. Damage to dopaminergic neurons by oxidative stress in Parkinson’s disease (Review). Int J Mol Med. 2018;41(4):1817-1825. https://doi.org/10.3892/ijmm.2018.3406
Wei Z, Li X, Li X, et al. Oxidative Stress in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front Mol Neurosci. 2018;11:236. https://doi.org/10.3389/fnmol.2018.00236
Vasenina EE, Levin OS. Oxidizing stress in patogeneza of neurodegenerate diseases: possibilities of therapy. Modern Therapy in Psychiatry and Neurology. 2013;(3-4):39-46. (In Russ.).
Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77-89.
Ellman QL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70-77. https://doi.org/10.1016/0003-9861(59)90090-6
Deponte M. Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta. 2013;1830(5):3217-3266. https://doi.org/10.1016/j.bbagen.2012.09.018
Mischley LK, Standish LJ, Weiss NS, et al. Glutathione as a Biomarker in Parkinson’s Disease: Associations with Aging and Disease Severity. Oxidative Medicine and Cellular Longevity. 2016;2016:9409363. https://doi.org/10.1155/2016/9409363
Cha SJ, Kim H, Choi H-J, et al. Protein Glutathionylation in the Pathogenesis of Neurodegenerative Diseases. Oxid Med Cell Longev. 2017;2017:2818565. https://doi.org/10.1155/2017/2818565

Close metadata